Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow IMMUNIC, INC.

Get SEC filing alerts via email and in your feed for IMMUNIC, INC.

IMUX

IMMUNIC, INC.

About IMMUNIC, INC.

Immunic, Inc. is a biotechnology company focused on developing oral immunology therapies for chronic inflammatory and autoimmune diseases, primarily multiple sclerosis. Its pipeline includes small molecule drugs targeting neuroprotection, immune modulation, and gastrointestinal regeneration. The company aims to provide disease-modifying treatments with neuroprotective, anti-inflammatory, and antiviral effects, leveraging clinical trials and strategic collaborations to address high unmet medical needs in neurology and gastroenterology markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from IMMUNIC, INC.

1
1
IMMUNIC, INC. Immunic Reports $32.6 Million Net Loss and $186.6 Million Cash Reserves in Latest 10-Q Filing

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
IMMUNIC, INC. Immunic Reports $97.2 Million Net Loss for Fiscal Year 2025, Focuses on Clinical Development

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
IMMUNIC, INC. Immunic Reports $25.6 Million Net Loss in Q3 2025, Faces Liquidity Challenges

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
IMMUNIC, INC. Immunic Reports $26.8 Million Net Loss in Q2 2025, Increases Operating Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
IMMUNIC, INC. Immunic Reports $25.5 Million Net Loss in Q1 2025, Faces Liquidity Challenges

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
IMMUNIC, INC. Immunic Reports $100.5 Million Net Loss for Fiscal Year 2024, Accumulated Deficit Reaches $511.4 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
IMMUNIC, INC. Immunic Reports Third Quarter Loss, Advances Clinical Programs and Leadership Team

Via official filing (AI summary) | over 1 year ago | 0 comments